Evidence map›Paper›PMID 38963657›Full record

ArticleJournal of neuro-oncology2024

Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.

Klaus-Henning Kahl, Philipp E Krauss, Maria Neu, Christoph J Maurer, Sabine Schill-Reiner, Zoha Roushan, Eva Laukmanis, Christian Dobner, Tilman Janzen, Nikolaos Balagiannis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Klaus-Henning KahlDepartment of Radiotherapy and Radio- Oncology, University Medical Center Augsburg, Augsburg, Germany. klaushenning.kahl@uk-augsburg.de.ORCID http://orcid.org/0000-0002-0545-1367
Philipp E KraussDepartment of Neurosurgery, University Medical Center Augsburg, Augsburg, Germany.
Maria NeuDepartment of Radiotherapy and Radio- Oncology, University Medical Center Augsburg, Augsburg, Germany.
Christoph J MaurerDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Medical Center Augsburg, Augsburg, Germany.
Sabine Schill-ReinerDepartment of Medical Physics and Radiation Protection, University Medical Center Augsburg, Augsburg, Germany.
Zoha RoushanDepartment of Medical Physics and Radiation Protection, University Medical Center Augsburg, Augsburg, Germany.
Eva LaukmanisDepartment of Medical Physics and Radiation Protection, University Medical Center Augsburg, Augsburg, Germany.
Christian DobnerDepartment of Medical Physics and Radiation Protection, University Medical Center Augsburg, Augsburg, Germany.
Tilman JanzenDepartment of Medical Physics and Radiation Protection, University Medical Center Augsburg, Augsburg, Germany.
Nikolaos BalagiannisDepartment of Radiotherapy and Radio- Oncology, University Medical Center Augsburg, Augsburg, Germany.
Björn SommerDepartment of Neurosurgery, University Medical Center Augsburg, Augsburg, Germany.
Georg StübenDepartment of Radiotherapy and Radio- Oncology, University Medical Center Augsburg, Augsburg, Germany.
Ehab ShibanDepartment of Neurosurgery, University Medical Center Augsburg, Augsburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStereotactic radiotherapy (SRT) is the predominant method for the irradiation of resection cavities after resection of brain metastases (BM). Intraoperative radiotherapy (IORT) with 50 kV x-rays is an alternative way to irradiate the resection cavity focally. We have already reported the outcome of our first 40 IORT patients treated until 2020. Since then, IORT has become the predominant cavity treatment in our center due to patients´ choice.

methodsWe retrospectively analyzed the outcomes of all patients who underwent resection of BM and IORT between 2013 and August 2023 at Augsburg University Medical Center (UKA).

resultsWe identified 105 patients with 117 resected BM treated with 50 kV x-ray IORT. Median diameter of the resected metastases was 3.1 cm (range 1.3 - 7.0 cm). Median applied dose was 20 Gy. All patients received standardized follow-up (FU) including three-monthly MRI of the brain. Mean FU was 14 months, with a median MRI FU for patients alive of nine months. Median overall survival (OS) of all treated patients was 18.2 months (estimated 1-year OS 57.7%). The observed local control (LC) rate of the resection cavity was 90.5% (estimated 1-year LC 84.2%). Distant brain control (DC) was 61.9% (estimated 1-year DC 47.9%). Only 16.2% of all patients needed WBI in the further course of disease. The observed radio necrosis rate was 2.6%.

conclusionAfter 117 procedures IORT still appears to be a safe and appealing way to perform cavity RT after neurosurgical resection of BM with low toxicity and excellent LC.

Indexed as

Brain NeoplasmsNeurosurgical ProceduresAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansIntraoperative CareMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeBrachytherapyBrain metastasisCavity RTFocal radiotherapyIORT

Identifiers

PMID38963657
PMCPMC11269407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.